Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile (MEDA)
22. mars 2013 oppdatert av: AAstrup, University of Copenhagen
Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile in Urine and Plasma in Overweight Adults
The purpose of this randomized, controlled, cross over single meal study is to investigate the metabolic effects of a breakfast rich in dairy proteins and to determine biomarkers for their intake.
The results from this project will increase our knowledge about nutritional value of dairy proteins, which is necessary to decide whether dairy products can be recommended for prevention of weight related bone loss.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
17
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Frederiksberg C
-
Copenhagen, Frederiksberg C, Danmark, 1958
- Department of Human Nutrition, University of Copenhagen
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 50 år (Voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Healthy males and females between 18 and 50 years
- BMI 25-40
Exclusion Criteria:
- Physical activity more than 10 hours weekly
- Smoking
- Diagnosed osteoporosis in at least one parent
- Dietary supplements and vitamin pills (during the study and 2 months before the start)
- Vegetarians and vegans
- Lactose intolerant
- Women who are pregnant, breastfeeding or post-menstrual
- Regular intake of medication
- Chronic diseases (including osteoporosis, cancer, diabetes, cardiovascular disease and mental disorders)
- Participation in other clinical trials that could affect the test results
- Donation of blod within 3 months before intervention start
- Hypersensitivity to paraaminobenzoic acid (PABA)
- Not able to comply with the procedures established by the Protocol
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Meal rich in dairy protein
|
Test meals with different protein types (dairy versus meat)
|
|
Eksperimentell: Meal rich in meat protein
|
Test meals with different protein types (dairy versus meat)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
serum C-terminal carboxy-terminal collagen crosslinks (CTX)
Tidsramme: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
urine C-terminal carboxy-terminal collagen
Tidsramme: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
|
serum osteocalcin (sOC)
Tidsramme: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
serum tartrate-resistant acid phosphatase (s-TRAP)
Tidsramme: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
urine deoxypyridinoline crosslink (uDPD)
Tidsramme: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
|
plasma metabolites for metabolomics analyses
Tidsramme: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
urine metabolites for metabolomics analyses
Tidsramme: baseline 24-h urine samples, 24-h urine samples after the meal test, urine samples at 2-h and 4-h after the meal test and urine samples from 4-h to 24-h, all at both visits
|
baseline 24-h urine samples, 24-h urine samples after the meal test, urine samples at 2-h and 4-h after the meal test and urine samples from 4-h to 24-h, all at both visits
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
serum insulin-growth factor-1 (IGF-1)
Tidsramme: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
serum insulin-growth factor binding-protein-3 (IGFBP-3)
Tidsramme: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
serum insulin
Tidsramme: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
serum glucose
Tidsramme: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
serum glukagon-like peptide-1 (GLP-1)
Tidsramme: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
urinary PABA
Tidsramme: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
|
urinary creatinin
Tidsramme: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
|
urinary biobank
Tidsramme: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
|
plasma biobank
Tidsramme: at 0, 30, 60, 90, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 90, 120, 180 and 240 min at both visits
|
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
weight
Tidsramme: at baseline at both visits
|
at baseline at both visits
|
|
height
Tidsramme: at baseline at the first visit
|
at baseline at the first visit
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. desember 2012
Primær fullføring (Faktiske)
1. februar 2013
Studiet fullført (Faktiske)
1. februar 2013
Datoer for studieregistrering
Først innsendt
15. januar 2013
Først innsendt som oppfylte QC-kriteriene
22. januar 2013
Først lagt ut (Anslag)
23. januar 2013
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
25. mars 2013
Siste oppdatering sendt inn som oppfylte QC-kriteriene
22. mars 2013
Sist bekreftet
1. mars 2013
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- M210
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .